10-Q · May 7, 2026
LeonaBio (LONA) reported a Q1 2026 net loss of $32.9 million, or $1.73 per share, a significant increase from the $9.1 million loss or $2.34 per share in Q1 2025. Total operating expenses rose to $17.2 million, driven…
Earnings analysis · 10-Q
LONA earnings analysis
Filed August 14, 2026 · Our reading of the company's report
The latest report
The supplied 10-Q text does not include the income statement, balance sheet, cash-flow statement or MD&A financial tables, so revenue, margins, EPS, free cash flow and segment trends cannot be assessed from the filing…
Read full summary
The supplied 10-Q text does not include the income statement, balance sheet, cash-flow statement or MD&A financial tables, so revenue, margins, EPS, free cash flow and segment trends cannot be assessed from the filing extract. The principal signal is financial strain: six-month net loss increased to $52.0 million from $16.1 million, while $51.1 million of cash and investments may not fund operations through at least the next 12 months. Capital access is further constrained because the $75.0 million ATM facility cannot currently be used through December 2026, while clinical, regulatory, supply-chain and third-party cybersecurity risks remain material.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
Cash balance remains $51.1 million
Management reported cash, cash equivalents and investments of $51.1 million as of June 30, 2026, providing a measurable liquidity base for ongoing development activities.
-
Prior financing provided $90 million gross proceeds
The December 2025 private placement provided approximately $90 million in gross proceeds, excluding placement agent fees and offering expenses, to support working capital and product-candidate development.
-
Disclosure controls assessed as effective
Management stated that disclosure controls and procedures were effective at the reasonable assurance level as of the period end, and that there were no material changes in internal control over financial reporting during the quarter ended June 30, 2026.
What to watch
-
Accelerating losses and liquidity shortfall
The company had net losses of $52.0 million for the six months ended June 30, 2026, versus $16.1 million in the prior-year period, and an accumulated deficit of $563.7 million. Management also stated that the $51.1 million liquidity balance may not fund operations and capital expenditures through at least the next 12 months.
-
Form S-3 ineligibility limits capital access
The company is currently unable to use its $75.0 million ATM facility because it is ineligible to use Form S-3 through December 2026 after failing to timely file a Form 8-K. This may delay or increase the cost of accessing capital and could force private financings or program reductions.
-
Large potential share overhang
Resale registration rights cover approximately 5.4 million common shares and approximately 58.6 million shares issuable upon exercise of prefunded warrants and warrants. These securities could create substantial future dilution and selling pressure.
-
Registration compliance could create damages
The company may owe liquidated damages equal to 1% of the aggregate purchase price per monthly period if it fails to maintain effectiveness of resale registration statements related to the December 2025 private placement and Sermonix pre-funded warrant issuance.
-
Trade restrictions threaten development supply chain
Newly emphasized trade and supply-chain risks include the BIOSECURE Act in the National Defense Authorization Act of 2026 and a planned 100% Section 232 tariff on certain patented and branded pharmaceutical products beginning September 29, 2026. These measures could disrupt third-party manufacturing, data-sharing and clinical supply arrangements.
-
Third-party cybersecurity risk increased
The filing identifies a cybersecurity attack at CRO Inotiv in August 2025 that temporarily disrupted its systems and operations. The company relies on CROs and other third parties for clinical development and states that loss or corruption of clinical-trial data could delay regulatory efforts and increase costs.
Management's outlook
No quantitative revenue or EPS guidance was provided in the supplied 10-Q text. Management states that cash, cash equivalents and investments of $51.1 million as of June 30, 2026 may not be sufficient to fund operating expenses and capital expenditures through at least the next 12 months.
Earlier filings 4
10-K · March 31, 2026
LeonaBio (LONA) repositioned from early-stage neuroscience toward a late-stage oncology opportunity by in‑licensing lasofoxifene in December 2025 to complement its in‑house ATH‑1105 program (Phase‑2 ready). The company…
10-Q · November 6, 2025
Athira reported a sharp reduction in operating spend in Q3 2025: total operating expenses for the three months ended September 30, 2025 were $6.9 million versus $29.6 million in Q3 2024, driving a narrower net loss of…
10-Q · August 7, 2025
Athira reported materially lower operating spend in 1H/2Q 2025 as part of its post-restructuring cost base: total operating expenses were $16.8M for the six months ended June 30, 2025 versus $55.7M in 1H 2024. Net loss…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.